The FDA has called out Bimbo Bakeries USA for misleading allergen labeling, raising concerns over consumer safety and transparency.
At a Glance
- Bimbo Bakeries USA is resisting FDA’s directive on allergen labeling.
- FDA cites misbranding for listing sesame and other allergens when absent.
- Bimbo argues its labeling aims to protect sesame allergy sufferers.
- FDA monitoring could lead to recalls or fines for non-compliance.
FDA Raises Concerns
The U.S. Food and Drug Administration has sent a warning to Bimbo Bakeries USA, citing misleading allergen information on several products. Inspections in late 2023 revealed inaccuracies, with items listing sesame, walnuts, and hazelnuts where none were present. The primary products involved include Sara Lee brand Artesano Brioche and Brownberry’s Whole Grains 12 Grains and Seeds.
The FDA’s actions stem from their drive to protect consumer interests, especially those who rely heavily on accurate food labeling to manage allergies. The misbranding is viewed as a violation of the Federal Food, Drug, and Cosmetic Act.
@US_FDA has issued a warning letter to Bimbo Bakeries USA, Inc. During two inspections in 2023, FDA found that some of the company’s bakery product labels listed major food allergens which were not actually included in the production formulations. https://t.co/m2cLFTEQnv
— U.S. FDA Human Foods Program (@FDAfood) June 25, 2024
Bimbo’s Defense and Response
Bimbo Bakeries USA has defended its labeling practices, claiming it’s designed to protect consumers with sesame allergies. “We think our approach is the most protective of sesame-allergic consumers,” asserted Bimbo Bakeries following the FDA’s warning.
The company indicates using universal packaging across products as a preventive measure against accidental consumption. However, the FDA disagreed with the logic, pushing for more transparent labeling, such as using “may contain” advisory spiels when necessary.
Implications for the Industry
This dispute between the FDA and Bimbo Bakeries underscores the complexity of allergen labeling in the commercial food sector. With the FASTER Act designating sesame as a major allergen, precision in labeling is pivotal to ensuring food safety and consumer trust. Bimbo’s current stance further emphasizes the tension between corporate practices and regulatory standards.
Food safety advocates argue that Bimbo’s practice limits choices for those allergic to sesame, eventually violating consumer rights. The situation presents a rare instance of a significant market player openly defying the FDA’s authority.